Biogen Inc. (NASDAQ:BIIB) Q2 2020 Earnings Conference Call - Final Transcript

Jul 22, 2020 • 08:00 am ET

Previous

Biogen Inc. (NASDAQ:BIIB) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Operator
Operator

[Operator Instructions] Our first question will come from the line of Cory Kasimov with JPMorgan.

Analyst
Cory Kasimov

Hey, great. Good morning, guys. Thanks for taking the question. Let me say Jeff it's been great working with [Technical Issues]. So my question is toward the recently-announced Phase III pre-symptomatic Alzheimer study. Can you elaborate on the rationale of choosing BAN2401 over aducanumab? I guess what about that -- how has that made it more attractive to initially move into the study? Is it the lack of required dose titrations or something else? Thanks a lot.

Executive
Alfred Sandrock, Jr.

Cory, this is Al Sandrock. I actually heard every third word of your question. So I'm not sure, but I think you were asking about BAN2401 in preclinical Alzheimer's disease and perhaps comparisons to aducanumab. If that's true, then I would say that, yes, BAN2401 and aducanumab are very similar antibodies. They both prefer to bind to aggregated forms of a-beta and they both show robust effect on amyloid PET imaging and also both have shown a reduction in clinical decline in Phase II or Phase 1 and Phase III trials. We have -- we're very excited that our partners at Eisai are initiating this clinical study with the Alzheimer's Disease Clinical Trials Consortium. I believe that starting earlier is the best approach for -- it turns out for all these neurological diseases and so we look forward to seeing the results of that. I'm not sure I heard your question but I hope I answered it.

Executive
Michel Vounatsos

So we did support the preclinical study with BAN2401 while we focused on the filing for aducanumab. We will revert back on lifecycle management opportunities during the entire continuum of the disease for patients once we have a readout and answer from the FDA on how we move forward.

Operator
Operator

Our next question comes from the line of Geoff Meacham with Bank of America.

Analyst
Geoff Meacham

Hey guys, thanks for the question. Jeff also want to say it's been great working with you. Another one on aducanumab. I know the next decision is -- the next step is a decision from FDA. But when you look at ENGAGE versus EMERGE, just wondering if you could go into any detail of the analysis over, say, the past six months to nine months that you guys have done with the FDA, whether that could be published or at a medical conference or anything that you can share with us in terms of what the developments have been over the past pretty much six -- since the beginning of this year. Thank you.

Executive
Alfred Sandrock, Jr.

So Geoff, just to make sure we get the gist of your question, you are asking more about the timing over the next few months?

Analyst
Geoff Meacham

No, no, just the quality of the analysis and the details of the data analysis for aducanumab in support of the filing.

Executive
Alfred Sandrock, Jr.

Well, I'm not sure I heard your question, Geoff. But I think -- look the filing is based on these studies; EMERGE, ENGAGE and PRIME. EMERGE is the